Earnings History Data for Keros Therapeutics (KROS) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Keros Therapeutics
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 28-02-2024 | AH | KROS | Keros Therapeutics | 1,980 | -1.34 | -1.38 | 0.00 | Keros Therapeutics GAAP EPS of -$1.34 beats by $0.04, revenue of $0.14M [2/28/2024 5:22 PM] |
67.52 | -0.55 (-0.81%) |
68.07 | 0.0 (0.00%) |
27.02 - 73.00 | 341,991 | 360,000 | 8,491 | ||
| 06-11-2023 | PM | KROS | Keros Therapeutics | 850.00 | -1.33 | -1.34 | 0.00 | Keros Therapeutics GAAP EPS of -$1.33 [11/6/2023 1:19 PM] |
31.68 | -0.26 (-0.81%) |
0.0 | 0.0 (0.00%) |
27.02 - 59.96 | 190,620 | 250,000 | 0 | ||
| 07-08-2023 | PM | KROS | Keros Therapeutics | 1,191 | -1.27 | -1.34 | 0.00 | Keros Therapeutics GAAP EPS of -$1.27 [8/7/2023 8:54 AM] |
40.45 | -0.68 (-1.64%) |
0.0 | 0.0 (0.00%) |
33.11 - 59.96 | 128,967 | 190,000 | 0 | ||
| 03-03-2023 | AH | After the close (Mar 3) |
KROS | Keros Therapeutics | 1,508 | -1.09 | -1.12 | 0.00 | Keros Therapeutics GAAP EPS of -$1.09 [3/3/2023 5:28 PM] |
52.45 | -6.88 (-11.59%) |
59.32 | 0.0 (0.00%) |
24.38 - 68.29 | 704,099 | 160,000 | 53,943 | |
|
|
||||||||||||||||||
| 09-03-2022 | AH | KROS | Keros Therapeutics | 1,172 | -0.30 | -0.94 | 0.00 | 53.51 | -0.45 (-0.83%) |
53.96 | 0.0 (0.00%) |
0.0 - 0.0 | 73,075 | 0 | 1,427 | |||
| 04-11-2021 | PM | KROS | Keros Therapeutics | 989.00 | -0.87 | -0.72 | 0.00 | Keros Therapeutics EPS misses by $0.15 [11/4/2021 9:24 AM] |
53.08 | 11.51 (27.69%) |
53.08 | 0.0 (0.00%) |
28.50 - 88.80 | 465,445 | 100,000 | 259 | ||
|
||||||||||||||||||
| 05-08-2021 | AH | KROS | Keros Therapeutics, Inc. | 810.00 | -0.67 | -0.66 | 0.00 | Keros Therapeutics EPS misses by $0.01 [8/5/2021 5:00 PM] |
35.88 | 0.91 (2.60%) |
34.97 | 0.0 (0.00%) |
33.27 - 88.80 | 69,325 | 90,000 | 534 | ||
| 06-05-2021 | AH | KROS | Keros Therapeutics, Inc. | 1,268 | -0.68 | -0.58 | 0.00 | Keros Therapeutics EPS misses by $0.10 [5/6/2021 5:00 PM] |
53.11 | -1.24 (-2.28%) |
53.11 | 0.0 (0.00%) |
25.60 - 88.80 | 117,815 | 190,000 | 1,998 | ||
| 25-03-2021 | PM | KROS | Keros Therapeutics, Inc. | 1,107 | -0.49 | -0.57 | 0.00 | Keros Therapeutics EPS beats by $0.08 [3/25/2021 9:05 AM] |
59.15 | 5.15 (9.54%) |
54.63 | 0.63 (1.17%) |
19.10 - 88.80 | 85,901 | 140,000 | 241 | ||
| 10-11-2020 | AH | KROS | Keros Therapeutics, Inc. | 1,120 | -0.60 | -0.58 | 0.00 | Keros Therapeutics EPS misses by $0.01 [11/10/2020 4:48 PM] |
54.42 | -2.24 (-3.95%) |
0.0 | 0.0 (0.00%) |
19.10 - 66.41 | 77,083 | 152,189 | 0 | ||
|
|
||||||||||||||||||